In patients suffering from cholangiocarcinoma, the occurrence of polyclonal (i.e., multiple) FGFR2 kinase domain mutations is frequently reported at progression on reversible FGFR inhibitors (21–23). The gene discussed is FGFR2; the disease is cholangiocarcinoma.